Zydus Marks Biosimilar Entry Into Mexico With Bevacizumab Approval
The Firm Showed Initial Interest In The Region Back In 2012, Calling It A Future Home Market
Marketed as Bhava, Zydus’ bevacizumab rival to Roche’s Avastin begins the firm’s biosimilar journey in the Latin American country.
